B-intervention	0	9	Letrozole
I-intervention	10	13	and
I-intervention	14	25	palbociclib
O	26	32	versus
B-control	33	45	chemotherapy
O	46	48	as
O	49	60	neoadjuvant
O	61	68	therapy
O	69	71	of
O	72	76	high
O	76	77	-
O	77	81	risk
O	82	89	luminal
O	90	96	breast
O	97	103	cancer
O	103	104	.

O	105	116	Palbociclib
O	117	119	is
O	120	121	a
O	122	126	CDK4
O	126	127	/
O	127	128	6
O	129	138	inhibitor
O	139	143	with
O	144	156	demonstrated
O	157	165	efficacy
O	166	169	and
O	170	176	safety
O	177	179	in
O	180	191	combination
O	192	196	with
O	197	206	endocrine
O	207	214	therapy
O	215	217	in
O	218	226	advanced
O	227	234	luminal
O	235	241	breast
O	242	248	cancer
O	249	250	(
O	250	253	LBC
O	253	254	)
O	254	255	.

O	256	258	We
O	259	268	evaluated
O	269	272	the
O	273	283	respective
O	284	292	efficacy
O	293	296	and
O	297	303	safety
O	304	306	of
O	307	319	chemotherapy
O	320	323	and
O	324	333	letrozole
O	333	334	-
O	334	345	palbociclib
O	346	347	(
O	347	353	LETPAL
O	353	354	)
O	355	366	combination
O	367	369	as
O	370	381	neoadjuvant
O	382	391	treatment
O	392	394	in
O	395	403	patients
O	404	408	with
O	409	413	high
O	413	414	-
O	414	418	risk
O	419	422	LBC
O	422	423	.

O	424	430	NeoPAL
O	431	432	(
O	432	438	UCBG10
O	438	439	/
O	439	440	4
O	440	441	,
O	442	453	NCT02400567
O	453	454	)
O	455	457	is
O	458	459	a
O	460	470	randomised
O	470	471	,
O	472	480	parallel
O	480	481	,
O	482	485	non
O	485	486	-
O	486	497	comparative
O	498	503	phase
O	504	506	II
O	507	512	study
O	512	513	.

B-eligibility	514	522	Patients
I-eligibility	523	527	with
I-eligibility	528	530	ER
I-eligibility	530	531	-
I-eligibility	531	539	positive
I-eligibility	539	540	,
I-eligibility	541	545	HER2
I-eligibility	545	546	-
I-eligibility	546	554	negative
I-eligibility	554	555	,
I-eligibility	556	564	Prosigna
I-eligibility	564	565	®
I-eligibility	565	566	-
I-eligibility	566	573	defined
I-eligibility	574	581	luminal
I-eligibility	582	583	B
I-eligibility	583	584	,
I-eligibility	585	587	or
I-eligibility	588	595	luminal
I-eligibility	596	597	A
I-eligibility	598	601	and
I-eligibility	602	606	node
I-eligibility	606	607	-
I-eligibility	607	615	positive
I-eligibility	615	616	,
I-eligibility	617	622	stage
I-eligibility	623	625	II
I-eligibility	625	626	-
I-eligibility	626	629	III
I-eligibility	630	636	breast
I-eligibility	637	643	cancer
I-eligibility	643	644	,
I-eligibility	645	648	not
I-eligibility	649	658	candidate
I-eligibility	659	662	for
I-eligibility	663	669	breast
I-eligibility	669	670	-
I-eligibility	670	680	conserving
I-eligibility	681	688	surgery
O	688	689	,
O	690	694	were
O	695	703	randomly
O	704	712	assigned
O	713	715	to
O	716	722	either
O	723	732	letrozole
O	733	734	(
O	734	735	2
O	735	736	.
O	736	737	5
O	738	740	mg
O	741	746	daily
O	746	747	)
O	748	751	and
O	752	763	palbociclib
O	764	765	(
O	765	768	125
O	769	771	mg
O	772	777	daily
O	777	778	,
O	779	780	3
O	781	786	weeks
O	786	787	/
O	787	788	4
O	788	789	)
O	790	796	during
O	797	799	19
O	800	805	weeks
O	805	806	,
O	807	809	or
O	810	812	to
O	813	819	FEC100
O	820	821	(
O	821	824	5FU
O	825	828	500
O	829	831	mg
O	831	832	/
O	832	834	m2
O	834	835	,
O	836	846	epirubicin
O	847	850	100
O	851	853	mg
O	853	854	/
O	854	856	m2
O	856	857	,
O	858	874	cyclophosphamide
O	875	878	500
O	879	881	mg
O	881	882	/
O	882	884	m2
O	884	885	)
O	885	886	×
O	886	887	3
O	888	890	21
O	890	891	-
O	891	894	day
O	895	902	courses
O	903	911	followed
O	912	914	by
O	915	924	docetaxel
O	925	928	100
O	929	931	mg
O	931	932	/
O	932	934	m2
O	934	935	×
O	935	936	3
O	937	939	21
O	939	940	-
O	940	943	day
O	944	951	courses
O	951	952	.

O	953	960	Primary
O	961	964	end
O	965	970	point
O	971	974	was
B-outcome-Measure	975	983	residual
I-outcome-Measure	984	990	cancer
I-outcome-Measure	991	997	burden
I-outcome-Measure	998	999	(
I-outcome-Measure	999	1002	RCB
I-outcome-Measure	1003	1004	0
I-outcome-Measure	1004	1005	-
I-outcome-Measure	1005	1006	I
I-outcome-Measure	1007	1011	rate
I-outcome-Measure	1011	1012	)
O	1012	1013	.

O	1014	1023	Secondary
O	1024	1027	end
O	1028	1034	points
O	1035	1043	included
B-outcome-Measure	1044	1052	clinical
I-outcome-Measure	1053	1061	response
O	1061	1062	,
B-outcome-Measure	1063	1076	proliferation
I-outcome-Measure	1076	1077	-
I-outcome-Measure	1077	1082	based
I-outcome-Measure	1083	1090	markers
O	1090	1091	,
O	1092	1095	and
B-outcome-Measure	1096	1102	safety
O	1102	1103	.

O	1104	1111	Overall
O	1111	1112	,
B-total-participants	1113	1116	106
O	1117	1125	patients
O	1126	1130	were
O	1131	1141	randomised
O	1142	1143	[
O	1143	1149	median
O	1150	1158	Prosigna
O	1158	1159	®
O	1160	1163	ROR
O	1164	1169	Score
O	1170	1172	71
O	1173	1174	(
O	1174	1176	22
O	1176	1177	-
O	1177	1179	93
O	1179	1180	)
O	1180	1181	]
O	1181	1182	.

B-outcome	1183	1186	RCB
I-outcome	1187	1188	0
I-outcome	1188	1189	-
I-outcome	1189	1190	I
O	1191	1194	was
O	1195	1203	observed
O	1204	1206	in
B-iv-bin-abs	1207	1211	four
O	1212	1215	and
B-cv-bin-abs	1216	1221	eight
O	1222	1230	patients
O	1231	1233	in
O	1234	1240	LETPAL
O	1241	1242	[
B-iv-bin-percent	1242	1243	7
I-iv-bin-percent	1243	1244	.
I-iv-bin-percent	1244	1245	7
I-iv-bin-percent	1245	1246	%
O	1247	1248	(
O	1248	1250	95
O	1250	1251	%
O	1252	1254	CI
O	1255	1256	0
O	1256	1257	.
O	1257	1258	4
O	1258	1259	-
O	1259	1261	14
O	1261	1262	.
O	1262	1263	9
O	1263	1264	)
O	1264	1265	]
O	1266	1269	and
O	1270	1282	chemotherapy
O	1283	1284	[
B-cv-bin-percent	1284	1286	15
I-cv-bin-percent	1286	1287	.
I-cv-bin-percent	1287	1288	7
I-cv-bin-percent	1288	1289	%
O	1290	1291	(
O	1291	1293	95
O	1293	1294	%
O	1295	1297	CI
O	1298	1299	5
O	1299	1300	.
O	1300	1301	7
O	1301	1302	-
O	1302	1304	25
O	1304	1305	.
O	1305	1306	7
O	1306	1307	)
O	1307	1308	]
O	1309	1313	arms
O	1313	1314	,
O	1315	1327	respectively
O	1327	1328	.

B-outcome	1329	1341	Pathological
I-outcome	1342	1350	complete
I-outcome	1351	1359	response
I-outcome	1360	1365	rates
O	1366	1370	were
B-iv-bin-percent	1371	1372	3
I-iv-bin-percent	1372	1373	.
I-iv-bin-percent	1373	1374	8
I-iv-bin-percent	1374	1375	%
O	1376	1379	and
B-cv-bin-percent	1380	1381	5
I-cv-bin-percent	1381	1382	.
I-cv-bin-percent	1382	1383	9
I-cv-bin-percent	1383	1384	%
O	1384	1385	.

B-outcome	1386	1394	Clinical
I-outcome	1395	1403	response
O	1404	1405	(
B-iv-bin-percent	1405	1407	75
I-iv-bin-percent	1407	1408	%
O	1408	1409	)
O	1410	1413	and
B-outcome	1414	1420	breast
I-outcome	1420	1421	-
I-outcome	1421	1431	conserving
I-outcome	1432	1439	surgery
I-outcome	1440	1445	rates
O	1446	1447	(
B-cv-bin-percent	1447	1449	69
I-cv-bin-percent	1449	1450	%
O	1450	1451	)
O	1452	1456	were
O	1457	1464	similar
O	1465	1467	in
O	1468	1472	both
O	1473	1477	arms
O	1477	1478	.

O	1479	1491	Preoperative
O	1492	1501	Endocrine
O	1502	1512	Prognostic
O	1513	1518	Index
O	1519	1520	0
O	1521	1527	scores
O	1528	1529	(
B-outcome	1529	1535	breast
I-outcome	1536	1542	cancer
I-outcome	1542	1543	-
I-outcome	1543	1551	specific
I-outcome	1552	1560	survival
O	1560	1561	)
O	1562	1566	were
O	1567	1575	observed
O	1576	1578	in
B-iv-bin-percent	1579	1581	17
I-iv-bin-percent	1581	1582	.
I-iv-bin-percent	1582	1583	6
I-iv-bin-percent	1583	1584	%
O	1585	1588	and
B-cv-bin-percent	1589	1590	8
I-cv-bin-percent	1590	1591	.
I-cv-bin-percent	1591	1592	0
I-cv-bin-percent	1592	1593	%
O	1594	1596	of
O	1597	1605	patients
O	1606	1608	in
O	1609	1615	LETPAL
O	1616	1619	and
O	1620	1632	chemotherapy
O	1633	1637	arms
O	1637	1638	,
O	1639	1651	respectively
O	1651	1652	.

O	1653	1659	Safety
O	1660	1667	profile
O	1668	1671	was
O	1672	1674	as
O	1675	1683	expected
O	1683	1684	,
O	1685	1689	with
B-iv-bin-abs	1690	1691	2
O	1692	1698	versus
B-cv-bin-abs	1699	1701	17
B-outcome	1702	1709	serious
I-outcome	1710	1717	adverse
I-outcome	1718	1724	events
O	1725	1726	(
O	1726	1735	including
B-cv-bin-abs	1736	1738	11
B-outcome	1739	1744	grade
I-outcome	1745	1746	4
I-outcome	1747	1754	serious
I-outcome	1755	1758	AEs
O	1759	1761	in
O	1762	1765	the
O	1766	1778	chemotherapy
O	1779	1782	arm
O	1782	1783	)
O	1783	1784	.

O	1785	1791	LETPAL
O	1792	1803	combination
O	1804	1807	was
O	1808	1818	associated
O	1819	1823	with
O	1824	1828	poor
B-outcome	1829	1841	pathological
I-outcome	1842	1850	response
O	1851	1854	but
O	1855	1866	encouraging
B-outcome	1867	1875	clinical
I-outcome	1876	1879	and
I-outcome	1880	1889	biomarker
I-outcome	1890	1899	responses
I-outcome	1900	1902	in
O	1903	1911	Prosigna
O	1911	1912	®
O	1912	1913	-
O	1913	1920	defined
O	1921	1925	high
O	1925	1926	-
O	1926	1930	risk
O	1931	1934	LBC
O	1934	1935	.

O	1936	1948	Contemporary
O	1949	1961	chemotherapy
O	1962	1969	regimen
O	1970	1973	was
O	1974	1984	associated
O	1985	1989	with
O	1990	1994	poor
O	1995	2007	pathological
O	2008	2011	and
O	2012	2021	biomarker
O	2022	2031	responses
O	2031	2032	,
O	2033	2037	with
O	2038	2039	a
O	2040	2044	much
O	2045	2049	less
O	2050	2060	favourable
O	2061	2067	safety
O	2068	2075	profile
O	2075	2076	.

O	2077	2083	LETPAL
O	2084	2095	combination
O	2096	2101	might
O	2102	2111	represent
O	2112	2114	an
O	2115	2126	alternative
O	2127	2129	to
O	2130	2142	chemotherapy
O	2143	2145	in
O	2146	2151	early
O	2152	2156	high
O	2156	2157	-
O	2157	2161	risk
O	2162	2165	LBC
O	2165	2166	.

O	2167	2178	NCT02400567
O	2178	2179	.
